These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 10657821)

  • 1. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Cho I; Reisinger K; Block SL; Wittes J; Iacuzio D; Piedra P; Treanor J; King J; Kotloff K; Bernstein DI; Hayden FG; Zangwill K; Yan L; Wolff M
    J Pediatr; 2000 Feb; 136(2):168-75. PubMed ID: 10657821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
    Nichol KL; Mendelman PM; Mallon KP; Jackson LA; Gorse GJ; Belshe RB; Glezen WP; Wittes J
    JAMA; 1999 Jul; 282(2):137-44. PubMed ID: 10411194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.
    Treanor JJ; Mattison HR; Dumyati G; Yinnon A; Erb S; O'Brien D; Dolin R; Betts RF
    Ann Intern Med; 1992 Oct; 117(8):625-33. PubMed ID: 1530193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.
    Zangwill KM; Droge J; Mendelman P; Marcy SM; Partridge S; Chiu CY; Jing J; Chang SJ; Cho I; Ward JI
    Pediatr Infect Dis J; 2001 Aug; 20(8):740-6. PubMed ID: 11734734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB; Gruber WC
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1947-51. PubMed ID: 11779396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
    Treanor JJ; Kotloff K; Betts RF; Belshe R; Newman F; Iacuzio D; Wittes J; Bryant M
    Vaccine; 1999 Dec; 18(9-10):899-906. PubMed ID: 10580204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren.
    Khan AS; Polezhaev F; Vasiljeva R; Drinevsky V; Buffington J; Gary H; Sominina A; Keitel W; Regnery H; Lonskaya NL; Doroshenko E; Gavrilov A; Ivakhov I; Arden N; Schonberger LB; Couch R; Kendal A; Cox N
    J Infect Dis; 1996 Feb; 173(2):453-6. PubMed ID: 8568310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.
    Bernstein DI; Yan L; Treanor J; Mendelman PM; Belshe R;
    Pediatr Infect Dis J; 2003 Jan; 22(1):28-34. PubMed ID: 12544405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.
    Belshe RB; Mendelman PM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):745-67. PubMed ID: 14753390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
    Halloran ME; Piedra PA; Longini IM; Gaglani MJ; Schmotzer B; Fewlass C; Herschler GB; Glezen WP
    Vaccine; 2007 May; 25(20):4038-45. PubMed ID: 17395338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of live attenuated influenza virus vaccine in the US.
    Belshe RB
    Virus Res; 2004 Jul; 103(1-2):177-85. PubMed ID: 15163507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
    Keitel WA; Couch RB; Quarles JM; Cate TR; Baxter B; Maassab HF
    J Infect Dis; 1993 Feb; 167(2):305-11. PubMed ID: 8421165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
    Longini IM; Halloran ME; Nizam A; Wolff M; Mendelman PM; Fast PE; Belshe RB
    Vaccine; 2000 Mar; 18(18):1902-9. PubMed ID: 10699339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.